Pelthos Therapeutics Inc. (PTHS) Stock Analysis

Pelthos Therapeutics Inc. (PTHS) is a publicly traded company in the HEALTHCARE sector. It trades at $26.05, carries a market capitalization of $91.06M. This page summarizes the public market data, fundamentals, and frequently asked questions for PTHS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

Market Sentiment

Pelthos Therapeutics Inc. currently has a Bullish sentiment score of 0.24.

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. is a biotechnology company headquartered in Durham, North Carolina, dedicated to the development and commercialization of groundbreaking therapeutic solutions for significant unmet medical needs. Utilizing advanced biopharmaceutical technologies and innovative research, Pelthos strives to improve the lives of patients facing complex health challenges. With a strong focus on pioneering treatments, the company is strategically positioned to capitalize on growth opportu...

GNG Research Analysis

GNG Research scores Pelthos Therapeutics Inc. (PTHS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PTHS.

Frequently Asked Questions

Does PTHS pay dividends?

Pelthos Therapeutics Inc. (PTHS) does not currently pay a regular dividend.

What is PTHS's market cap?

Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $91.06M with a current stock price of $26.05.